Preclinical murine studies that evaluated the combination of chemotherapy or immunotherapy with known cDC1 boosters have found a decrease in tumor progression and enhanced cytotoxic T lymphocyte (CTL) activation as well as increased maturation of cDC1 (27). This evidence concerns the gene MPPE1 and neoplasm.